NasdaqGM - Delayed Quote USD

Ligand Pharmaceuticals Incorporated (LGND)

70.57 +0.20 (+0.28%)
At close: April 26 at 4:00 PM EDT
70.57 0.00 (0.00%)
After hours: April 26 at 4:02 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
131,314.00
131,314.00
196,245.00
241,544.00
163,562.00
Cost of Revenue
10,512.00
10,512.00
52,827.00
62,176.00
30,419.00
Gross Profit
120,802.00
120,802.00
143,418.00
179,368.00
133,143.00
Operating Expense
110,981.00
110,981.00
140,381.00
75,517.00
112,757.00
Operating Income
9,821.00
9,821.00
3,037.00
103,851.00
20,386.00
Net Non Operating Interest Income Expense
7,055.00
7,055.00
247.00
-18,733.00
-19,337.00
Other Income Expense
46,784.00
46,784.00
32,727.00
-12,913.00
243.00
Pretax Income
63,660.00
63,660.00
36,011.00
72,205.00
1,292.00
Tax Provision
9,841.00
9,841.00
41,230.00
-4,148.00
-5,306.00
Net Income Common Stockholders
52,154.00
52,154.00
-33,361.00
57,138.00
-2,985.00
Diluted NI Available to Com Stockholders
52,154.00
52,154.00
-33,361.00
57,138.00
-2,985.00
Basic EPS
0.93
3.02
-1.98
3.44
-0.18
Diluted EPS
0.87
2.94
-1.98
3.31
-0.18
Basic Average Shares
17,153.75
17,298.00
16,868.00
16,630.00
16,185.00
Diluted Average Shares
17,360.00
17,757.00
16,868.00
17,246.00
16,825.00
Total Operating Income as Reported
11,942.00
11,942.00
3,037.00
103,851.00
37,500.00
Total Expenses
121,493.00
121,493.00
193,208.00
137,693.00
143,176.00
Net Income from Continuing & Discontinued Operation
52,154.00
52,154.00
-33,361.00
57,138.00
-2,985.00
Normalized Income
12,616.95
12,393.40
-27,765.60
80,194.99
6,465.87
Interest Income
7,711.00
7,711.00
2,046.00
886.00
8,078.00
Interest Expense
656.00
656.00
1,799.00
19,619.00
27,415.00
Net Interest Income
7,055.00
7,055.00
247.00
-18,733.00
-19,337.00
EBIT
64,316.00
64,316.00
37,810.00
91,824.00
28,707.00
EBITDA
99,959.00
99,959.00
89,180.00
142,770.00
56,673.00
Reconciled Cost of Revenue
8,523.00
8,523.00
35,694.00
45,452.00
14,095.00
Reconciled Depreciation
35,643.00
35,643.00
51,370.00
50,946.00
27,966.00
Net Income from Continuing Operation Net Minority Interest
53,819.00
53,819.00
-5,219.00
76,353.00
6,598.00
Total Unusual Items Excluding Goodwill
48,736.00
48,736.00
28,540.00
-5,263.00
181.00
Total Unusual Items
48,736.00
48,736.00
28,540.00
-5,263.00
181.00
Normalized EBITDA
51,223.00
51,223.00
60,640.00
148,033.00
56,492.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
7,533.95
7,310.40
5,993.40
-1,421.01
48.87
12/31/2020 - 11/18/1992

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OABI OmniAb, Inc.
4.4800
+1.13%
 
TVTX Travere Therapeutics, Inc.
5.26
-2.41%
 
FOLD Amicus Therapeutics, Inc.
10.28
+1.08%
 
AKRO Akero Therapeutics, Inc.
19.74
+4.28%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
ETNB 89bio, Inc.
8.26
+0.12%
 
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%
 
XNCR Xencor, Inc.
19.98
+3.90%
 
KURA Kura Oncology, Inc.
19.65
+3.42%